Suneel Research Foundation
- Assets
- $434.3k
- Revenue
- $75.1k
- Investments
- $0.0
- Employees
- 0
- Location
- Buffalo, NY
- Founding
- 07/2003
- Data as of
- 12/2023
- EIN
- 03-0436723
Organization Overview
Suneel Research Foundation is located in Buffalo, NY. The organization was established in 2003. According to its NTEE Classification (T03) the organization is classified as: Professional Societies & Associations, under the broad grouping of Philanthropy, Voluntarism & Grantmaking Foundations and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Suneel Research Foundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Suneel Research Foundation generated $75.1k in total revenue. The organization has seen a slow decline revenue. Over the past 8 years, revenues have fallen by an average of (1.2%) each year. All expenses for the organization totaled $50.8k during the year ending 12/2023. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
THE FOUNDATION RAISES MONEY TO FOSTER AND ADVANCE MEDICAL AND SCIENTIFIC RESEARCH TO FIND A CURE FOR DUCHENNE'S MUSCULAR DYSTROPHY. IN ADDITION, THE FOUNDATION SEEKS TO PREVENT AND ALLEVIATE SUFFERING & PROMOTE EDUCATION & AWARENESS OF DUCHENNE'S MUSCULAR DYSTROPHY.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE FOUNDATION FUNDS RESEARCH ACTIVITIES TO FIND A CURE FOR DUCHENNE'S MUSCULAR DYSTROPHY (DMD). CURRENTLY THERE ARE A NUMBER OF CLINICAL TRIALS UNDERWAY FOR DRUGS DEVELOPED TO TREAT VARIOUS ASPECTS OF DMD. IN SEPTEMBER 2016, SAREPTA THERAPEUTICS, WON FDA APPROVAL FOR THE USE OF ITS DRUG EXONDYS 51 FOR THE TREATMENT OF DMD PATIENTS THAT HAVE A CONFIRMED MUTATION OF THE DYSTROPHIN GENE AMENABLE TO EXON 51 SKIPPING. IN DECEMBER 2019, SAREPTA, WON FDA APPROVAL FOR ITS NEW DRUG VYONDYS 53 FOR THE TREATMENT OF PATIENTS THAT HAVE A CONFIRMED MUTATION OF THE DYSTROPHIN GENE CONNECTED TO EXON 53 SKIPPING. BOTH TREATMENTS HELP APPROXIMATELY 21% OF THE PATIENTS AFFLICTED WITH DMD.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Thomas A Maher CPA President | OfficerTrustee | 10 | $0 |
Kenneth Manning ESQ Secretary | OfficerTrustee | 5 | $0 |
Neera Gulati MD Director | Trustee | 5 | $0 |
David J Korzak Director | Trustee | 5 | $0 |
William Christ ESQ Director | Trustee | 5 | $0 |
George Hajduczok ESQ Director | Trustee | 5 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $67,018 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $67,018 |
| Total Program Service Revenue | $0 |
| Investment income | $8,069 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $75,087 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $48,000 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $0 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $0 |
| Advertising and promotion | $236 |
| Office expenses | $431 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $0 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $768 |
| All other expenses | $0 |
| Total functional expenses | $50,845 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $134,282 |
| Savings and temporary cash investments | $300,000 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $434,282 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $0 |
| Net assets without donor restrictions | $0 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $434,282 |
| Total liabilities and net assets/fund balances | $434,282 |
Grants Awarded
Over the last fiscal year, Suneel Research Foundation has awarded $92,000 in support to 2 organizations.
| Grant Recipient | Amount |
|---|---|
NATIONAL WRITING PROJECT PURPOSE: BOOK PUBLICATION | $75,000 |
CHARLEY'S FUND INC PURPOSE: FUND MEDICAL SUPPLIES | $17,000 |